Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies

References

• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22(1):329–18. doi:10.1146/annurev.immunol.22.012703.104803.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Scheper W, Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2019;37(1):173–200. doi:10.1146/annurev-immunol-042617-053402.
   PubMedGoogle Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8. doi:10.1038/NI1102-991.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–46. doi:10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Haen SP, Löffler MW, Rammensee HG, Brossart P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol. 2020;17(10):595–610. doi:10.1038/S41571-020-0387-X.
   PubMed Web of Science ®Google Scholar
• Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59–73. doi:10.1038/CR.2016.153.
   PubMed Web of Science ®Google Scholar
• Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L. et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25(5):767–75. doi:10.1038/S41591-019-0434-2.
   PubMed Web of Science ®Google Scholar
• Xia H, McMichael J, Becker-Hapak M, Onyeador OC, Buchli R, McClain E, Pence P, Supabphol S, Richters MM, Basu A. et al. Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. Sci Immunol. 2023;8(82). doi:10.1126/SCIIMMUNOL.ABG2200.
   Web of Science ®Google Scholar
• Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18(8):1009–21. doi:10.1016/S1470-2045(17)30516-8.
   PubMed Web of Science ®Google Scholar
• van Belzen IAEM, Schönhuth A, Kemmeren P, Hehir-Kwa JY. Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology. Npj Precis Oncol. 2021;5(1). doi: 10.1038/S41698-021-00155-6.
   PubMed Web of Science ®Google Scholar
• Wang N, Lysenkov V, Orte K, Kairisto V, Aakko J, Khan S, Elo LL, Kosakovsky Pond SL. Tool evaluation for the detection of variably sized indels from next generation whole genome and targeted sequencing data. PLoS Comput Biol. 2022;18(2):e1009269. doi:10.1371/JOURNAL.PCBI.1009269.
   PubMed Web of Science ®Google Scholar
• Monaghan L, Longman D, Cáceres JF. Translation-coupled mRNA quality control mechanisms. EMBO J. 2023;42(19):e114378. doi:10.15252/EMBJ.2023114378.
   PubMed Web of Science ®Google Scholar
• Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM. et al. T-cell responses to TP53 “hotspot” mutations and unique neoantigens expressed by human ovarian cancers. Clin Cancer Res. 2018;24(22):5562–73. doi:10.1158/1078-0432.CCR-18-0573.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A. et al. Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers. Cancer Discov. 2019;9(8):1022–35. doi:10.1158/2159-8290.CD-18-1494.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125(10):3981–91. doi:10.1172/JCI82416.
   PubMed Web of Science ®Google Scholar
• Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153–68. doi:10.1038/S41575-019-0245-4.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM. et al. T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–62. doi:10.1056/NEJMOA1609279.
   PubMed Web of Science ®Google Scholar
• Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell. 2020;38(4):454–72. doi:10.1016/J.CCELL.2020.07.013.
   PubMed Web of Science ®Google Scholar
• Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1). doi:10.1038/S41392-022-01270-X.
   Web of Science ®Google Scholar
• Pearlman AH, Hwang MS, Konig MF, Hsiue EHC, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB. et al. Targeting public neoantigens for cancer immunotherapy. Nat Cancer. 2021;2(5):487–97. doi:10.1038/S43018-021-00210-Y.
   PubMedGoogle Scholar
• Gurung HR, Heidersbach AJ, Darwish M, Chan PPF, Li J, Beresini M, Zill OA, Wallace A, Tong AJ, Hascall D. et al. Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types. Nat Biotechnol. 2023. doi:10.1038/S41587-023-01945-Y.
   PubMed Web of Science ®Google Scholar
• Wu H-X, Wang Z-X, Zhao Q, Chen D-L, He M-M, Yang L-P, Wang Y-N, Jin Y, Ren C, Luo H-Y. et al. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann Transl Med. 2019;7(22):640–640. doi:10.21037/ATM.2019.10.116.
   PubMed Web of Science ®Google Scholar
• DI VL, Reijmers RM, Honders MW, Hagedoorn RS, De Jong RCM, Kester MGD, Van Der Steen DM, De Ru AH, Kweekel C, Bijen HM. et al. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J Clin Invest. 2019;129(2):774–85. doi:10.1172/JCI97482.
   PubMed Web of Science ®Google Scholar
• Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz MK. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001;93(1):6–11. doi:10.1002/IJC.1298.
   PubMed Web of Science ®Google Scholar
• Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol. 2004;172(10):6057–64. doi:10.4049/JIMMUNOL.172.10.6057.
   PubMed Web of Science ®Google Scholar
• Hansen UK, Ramskov S, Bjerregaard AM, Borch A, Andersen R, Draghi A, Donia M, Bentzen AK, Marquard AM, Szallasi Z. et al. Tumor-infiltrating T cells from clear cell renal cell carcinoma patients recognize neoepitopes derived from point and frameshift mutations. Front Immunol. 2020;11:11. doi:10.3389/FIMMU.2020.00373.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi T, Song X, Liu B, Wei J. Gene fusion neoantigens: emerging targets for cancer immunotherapy. Cancer Lett. 2021;506:45–54. doi:10.1016/j.canlet.2021.02.023.
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Riva G, Barozzi P, Guido I, Gurrado A, Quartuccio G, Rubert L, Lagreca I, Vallerini D. et al. BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. Blood. 2017;129(5):582–6. doi:10.1182/BLOOD-2016-07-731091.
   PubMed Web of Science ®Google Scholar
• Wei Z, Zhou C, Zhang Z, Guan M, Zhang C, Liu Z, Liu Q. The landscape of tumor fusion neoantigens: a pan-cancer analysis. iScience. 2019;21:249–60. doi:10.1016/J.ISCI.2019.10.028.
   PubMed Web of Science ®Google Scholar
• Biswas N, Chakrabarti S, Padul V, Jones LD, Ashili S. Designing neoantigen cancer vaccines, trials, and outcomes. Front Immunol. 2023;14. doi:10.3389/FIMMU.2023.1105420.
   Web of Science ®Google Scholar
• Okada M, Shimizu K, Fujii SI. Identification of neoantigens in cancer cells as targets for immunotherapy. Int J Mol Sci. 2022;23(5):2594. doi:10.3390/IJMS23052594.
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock GM, Wilson RK, Ding L. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25(17):2283–5. doi:10.1093/BIOINFORMATICS/BTP373.
   PubMed Web of Science ®Google Scholar
• Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, Ley TJ, Mardis ER, Wilson RK, Ding L. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28(3):311–7. doi:10.1093/BIOINFORMATICS/BTR665.
   PubMed Web of Science ®Google Scholar
• Yang R, Van Etten JL, Dehm SM. Indel detection from DNA and RNA sequencing data with transIndel. Bmc Genom. 2018;19(1). doi: 10.1186/S12864-018-4671-4.
   Google Scholar
• Wajnberg G, Passetti F. Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery. Expert Opin Drug Discov. 2016;11(3):257–68. doi:10.1517/17460441.2016.1143813.
   PubMed Web of Science ®Google Scholar
• Sun Z, Bhagwate A, Prodduturi N, Yang P, Kocher JPA. Indel detection from RNA-seq data: tool evaluation and strategies for accurate detection of actionable mutations. Brief Bioinform. 2017;18(6):973–83. doi:10.1093/BIB/BBW069.
   PubMed Web of Science ®Google Scholar
• Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9. doi:10.1038/NBT.2514.
   PubMed Web of Science ®Google Scholar
• Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL, Griffith M. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 2019;11(1). doi: 10.1186/S13073-019-0666-2.
   PubMed Web of Science ®Google Scholar
• Hundal J, Kiwala S, McMichael J, Miller CA, Xia H, Wollam AT, Liu CJ, Zhao S, Feng YY, Graubert AP. et al. PVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res. 2020;8(3):409–20. doi:10.1158/2326-6066.CIR-19-0401.
   PubMed Web of Science ®Google Scholar
• Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K. et al. Challenges in neoantigen-directed therapeutics. Cancer Cell. 2023;41(1):15–40. doi:10.1016/J.CCELL.2022.10.013.
   PubMed Web of Science ®Google Scholar
• Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183(3):818–34.e13. doi:10.1016/j.cell.2020.09.015.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (80-). 2016;351(6280):1463–9. doi:10.1126/science.aaf1490.
   PubMed Web of Science ®Google Scholar
• Cuevas MVR, Hardy MP, Larouche JD, Apavaloaei A, Kina E, Vincent K, Gendron P, Laverdure JP, Durette C, Thibault P. et al. BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens. Genome Biol. 2023;24(1). doi:10.1186/S13059-023-03029-1
   PubMed Web of Science ®Google Scholar
• Liepe J, Marino F, Sidney J, Jeko A, Bunting DE, Sette A, Kloetzel PM, Stumpf MPH, Heck AJR, Mishto M. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Sci. 2016;354(6310):354–8. doi:10.1126/SCIENCE.AAF4384.
   PubMed Web of Science ®Google Scholar
• Falk K, Rötzschke O, Stevanovié S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351(6324):290–6. doi:10.1038/351290A0.
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Cox AL, Stover JM, Moore MM, Hunt DF, Engelhard VH. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res. 1994;54:2731–7.
   PubMed Web of Science ®Google Scholar
• Shapiro IE, Bassani-Sternberg M. The impact of immunopeptidomics: from basic research to clinical implementation. Semin Immunol. 2023;66:101727. doi:10.1016/J.SMIM.2023.101727.
   PubMed Web of Science ®Google Scholar
• Olsson N, Heberling ML, Zhang L, Jhunjhunwala S, Phung QT, Lin S, Anania VG, Lill JR, Elias JE. An integrated genomic, proteomic, and immunopeptidomic approach to discover treatment-induced neoantigens. Front Immunol. 2021;12:12. doi:10.3389/FIMMU.2021.662443.
   Web of Science ®Google Scholar
• Li X, Pak HS, Huber F, Michaux J, Taillandier-Coindard M, Altimiras ER, Bassani-Sternberg M. A microfluidics-enabled automated workflow of sample preparation for MS-based immunopeptidomics. Cell Reports Methods. 2023;3(6):100479. doi:10.1016/J.CRMETH.2023.100479.
   PubMedGoogle Scholar
• Stutzmann C, Peng J, Wu Z, Savoie C, Sirois I, Thibault P, Wheeler AR, Caron E. Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery. Cell Reports Methods. 2023;3(6):100511. doi:10.1016/J.CRMETH.2023.100511.
   PubMedGoogle Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–52. doi:10.1038/NM.3161.
   PubMed Web of Science ®Google Scholar
• Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME. et al. The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunol Res. 2018;6(8):888–99. doi:10.1158/2326-6066.CIR-18-0129.
   PubMed Web of Science ®Google Scholar
• Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJS, McGranahan N, Rosenthal R. et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol. 2016;34(10):1037–45. doi:10.1038/NBT.3662.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Rosenberg SA. “Final common pathway” of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18(3):255–62. doi:10.1038/NI.3682.
   PubMed Web of Science ®Google Scholar
• Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ. et al. Exploring the immunogenicity of noncanonical HLA-I tumor ligands identified through proteogenomics. Clin Cancer Res. 2023;29(12):2250–65. doi:10.1158/1078-0432.CCR-22-3298.
   PubMed Web of Science ®Google Scholar
• Repáraz D, Ruiz M, Llopiz D, Silva L, Vercher E, Aparicio B, Egea J, Tamayo-Uria I, Hervás-Stubbs S, García-Balduz J. et al. Neoantigens as potential vaccines in hepatocellular carcinoma. J Immunother Cancer. 2022;10(2):e003978. doi:10.1136/JITC-2021-003978.
   PubMed Web of Science ®Google Scholar
• Aparicio B, Repáraz D, Ruiz M, Llopiz D, Silva L, Theunissen P, Tamayo I, Smerdou C, Igea A, Santisteban M. et al. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer. Front Immunol; 2022;13:985886. doi:10.3389/fimmu.2022.985886.
   Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021;39(2):154–73. doi:10.1016/j.ccell.2020.10.001.
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–72. doi:10.1016/j.annonc.2021.02.006.
   PubMed Web of Science ®Google Scholar
• Montesion M, Murugesan K, Jin DX, Sharaf R, Sanchez N, Guria A, Minker M, Li G, Fisher V, Sokol ES. et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 2021;11(2):282–92. doi:10.1158/2159-8290.CD-20-0672.
   PubMed Web of Science ®Google Scholar
• Koopman LA, Corver WE, VanDer Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med. 2000;191(6):961–75. doi:10.1084/JEM.191.6.961.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259–71.e11. doi:10.1016/J.CELL.2017.10.001.
   PubMed Web of Science ®Google Scholar
• Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, Stevens J, Lane WJ, Dellagatta JL, Steelman S. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152–8. doi:10.1038/NBT.3344.
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–5. doi:10.1038/nature14404.
   PubMed Web of Science ®Google Scholar
• Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711–23.e4. doi:10.1016/J.CCELL.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25(10):3074–83. doi:10.1158/1078-0432.CCR-18-1942.
   PubMed Web of Science ®Google Scholar
• Ishino T, Kawashima S, Tanji E, Ueno T, Ueda Y, Ogasawara S, Sato K, Mano H, Ishihara S, Kato N. et al. Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. Br J Cancer. 2023;128(6):1166–75. doi:10.1038/S41416-023-02165-6.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29. doi:10.1056/NEJMOA1604958.
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201. doi:10.1158/2159-8290.CD-16-1223.
   PubMed Web of Science ®Google Scholar
• Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B. et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8(1). doi:10.1038/NCOMMS15440.
   PubMedGoogle Scholar
• Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202–16. doi:10.1158/2159-8290.CD-15-0283.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M. et al. An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity. 2020;53(1):187–203.e8. doi:10.1016/J.IMMUNI.2020.06.016.
   PubMed Web of Science ®Google Scholar
• Peña CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, Miller DS, Lea JS, Wong KK, DeBerardinis RJ. et al. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest. 2015;125(11):4063–76. doi:10.1172/JCI82152.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL. et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016;76(5):999–1008. doi:10.1158/0008-5472.CAN-15-1439.
   PubMed Web of Science ®Google Scholar
• Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HKM, Vaske C, Siegel JU, Troyanskaya O, Chin SF, Caldas C. et al. Lymphocyte invasion in IC10/Basal-like breast tumors is associated with wild-type TP53. Mol Cancer Res. 2015;13(3):493–501. doi:10.1158/1541-7786.MCR-14-0387.
   PubMed Web of Science ®Google Scholar
• Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med. 2013;210(10):2057–69. doi:10.1084/JEM.20130783.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44. doi:10.1038/NATURE08617.
   PubMed Web of Science ®Google Scholar
• Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127(4):1425–37. doi:10.1172/JCI90644.
   PubMed Web of Science ®Google Scholar
• Ilyas S, Yang JC. Landscape of tumor antigens in T cell immunotherapy. J Immunol. 2015;195(11):5117–22. doi:10.4049/JIMMUNOL.1501657.
   PubMed Web of Science ®Google Scholar
• Vigneron N. Human tumor antigens and cancer immunotherapy. Biomed Res Int. 2015;2015:1–17. doi:10.1155/2015/948501.
   Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (80-). 1996;271(5256):1734–6. doi:10.1126/science.271.5256.1734.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–7. doi:10.1073/pnas.192461099.
   PubMed Web of Science ®Google Scholar
• Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11(4):838–57. doi:10.1158/2159-8290.CD-20-1680.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. doi:10.1056/NEJMoa1406498.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Sci. 2015;350(6257):207–11. doi:10.1126/SCIENCE.AAD0095.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS. et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science (80-). 2015;348(6230):124–8. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659–70. doi:10.1016/S1470-2045(22)00197-8.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. doi:10.1056/NEJMOA1500596.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1. doi:10.1056/NEJMc1713444.
   PubMed Web of Science ®Google Scholar
• Zou XL, Li XB, Ke H, Zhang GY, Tang Q, Yuan J, Zhou CJ, Zhang JL, Zhang R, Chen WY. Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer. Front Immunol. 2021;12:12. doi:10.3389/FIMMU.2021.689076.
   Google Scholar
• Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S. et al. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer. 2023;11(8):e007440. doi:10.1136/JITC-2023-007440.
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(5):661–72. doi:10.1016/J.ANNONC.2021.02.006.
   PubMed Web of Science ®Google Scholar
• Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, Purandare B, An D, Quach BB, Nguyen D. et al. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023;615(7953):697–704. doi:10.1038/S41586-023-05787-1.
   PubMed Web of Science ®Google Scholar
• Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, Maher C, Regazzi A, Wong P, Al-Ahmadie H. et al. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nat Commun. 2022;13(1). doi:10.1038/S41467-022-29342-0
   Web of Science ®Google Scholar
• Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US. et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol. 2016;34(20):2389–97. doi:10.1200/JCO.2016.66.7220.
   PubMed Web of Science ®Google Scholar
• Lu Y-C, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA. et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013;190(12):6034–42. doi:10.4049/JIMMUNOL.1202830.
   PubMed Web of Science ®Google Scholar
• Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y. et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20(13):3401–10. doi:10.1158/1078-0432.CCR-14-0433.
   PubMed Web of Science ®Google Scholar
• Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF. et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol Res. 2016;4(8):669–78. doi:10.1158/2326-6066.CIR-15-0215.
   PubMed Web of Science ®Google Scholar
• Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (1991). 2005;28(1):53–62. doi:10.1097/00002371-200501000-00007.
   PubMed Web of Science ®Google Scholar
• Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer. 1996;65(4):413–21. doi:10.1002/(SICI)1097-0215(19960208)65:4<413:AID-IJC3>3.0.CO;2-#.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Sci. 2015;348(6230):62–8. doi:10.1126/SCIENCE.AAA4967.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Sci. 2014;344(6184):641–5. doi:10.1126/SCIENCE.1251102.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–30. doi:10.1038/S41591-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC. et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res. 2022;10(8):932–46. doi:10.1158/2326-6066.CIR-22-0040.
   PubMed Web of Science ®Google Scholar
• Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA. Adoptive cell therapy–tumor-infiltrating lymphocytes, T-Cell receptors, and chimeric antigen receptors. Semin Oncol. 2015;42(4):626–39. doi:10.1053/J.SEMINONCOL.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (1991). 2013;36(2):133–51. doi:10.1097/CJI.0b013e3182829903.
   PubMed Web of Science ®Google Scholar
• Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y-P, Leung A, Payne R, Sutcliffe K, Cramer J. et al. Neoantigen T-Cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112–9. doi:10.1056/NEJMOA2119662.
   PubMed Web of Science ®Google Scholar
• Wang QJ, Yu Z, Griffith K, Hanada KI, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-Mutated human tumors. Cancer Immunol Res. 2016;4(3):204–14. doi:10.1158/2326-6066.CIR-15-0188.
   PubMed Web of Science ®Google Scholar
• Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K. et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat Commun. 2021;12(1). doi:10.1038/S41467-021-24562-2
   Web of Science ®Google Scholar
• Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT. et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun. 2019;10(1). doi:10.1038/S41467-019-08304-Z
   PubMedGoogle Scholar
• Monach PA, SC M, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995;2(1):45–59. doi:10.1016/1074-7613(95)90078-0.
   PubMed Web of Science ®Google Scholar
• Matsutake T, Srivastava PK. The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci U S A. 2001;98(7):3992–7. doi:10.1073/PNAS.071523398.
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):1081–91. doi:10.1158/0008-5472.CAN-11-3722.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81. doi:10.1038/NATURE13988.
   PubMed Web of Science ®Google Scholar
• Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, Blanchard T, McMahon D, Sidney J, Sette A. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med. 2014;211(11):2231–48. doi:10.1084/jem.20141308.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572–6. doi:10.1038/nature14001.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrors B, Vascotto F, Castle JC. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692–6. doi:10.1038/nature14426.
   PubMed Web of Science ®Google Scholar
• Niemi JVL, Sokolov AV, Schiöth HB. Neoantigen vaccines; clinical trials, classes, indications, adjuvants and combinatorial treatments. Cancers Basel. 2022;14(20):5163. doi:10.3390/cancers14205163.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie W-R, Hildebrand WH, Mardis ER. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Sci. 2015;348(6236):803–8. doi:10.1126/science.aaa3828.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6. doi:10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–5. doi:10.1038/S41586-018-0810-Y.
   PubMed Web of Science ®Google Scholar
• Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–9. doi:10.1038/s41586-018-0792-9.
   PubMed Web of Science ®Google Scholar
• Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976–88. doi:10.1172/JCI134915.
   PubMed Web of Science ®Google Scholar
• Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y. et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021 61;6(1):1–12. doi:10.1038/s41392-020-00448-5.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang S, Han N, Jiang J, Xu Y, Ma D, Lu L, Guo X, Qiu M, Huang Q. et al. A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment. Front Immunol. 2021;12. doi:10.3389/FIMMU.2021.691605.
   Web of Science ®Google Scholar
• Cai Z, Su X, Qiu L, Li Z, Li X, Dong X, Wei F, Zhou Y, Luo L, Chen G. et al. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer. 2021;20(1):164. doi:10.1186/S12943-021-01467-8.
   PubMed Web of Science ®Google Scholar
• Fang Y, Mo F, Shou J, Wang H, Luo K, Zhang S, Han N, Li H, Ye S, Zhou Z. et al. A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors. Clin Cancer Res. 2020;26(17):4511–20. doi:10.1158/1078-0432.CCR-19-2881.
   PubMed Web of Science ®Google Scholar
• Kloor M, Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Al-Batran SE, Tariverdian M, Jäger E, von Knebel Doeberitz M. A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial. Clin Cancer Res. 2020;26(17):4503–10. doi:10.1158/1078-0432.CCR-19-3517.
   PubMed Web of Science ®Google Scholar
• Leoni G, D’Alise AM, Cotugno G, Langone F, Garzia I, de Lucia M, Fichera I, Vitale R, Bignone V, Tucci FG. et al. A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability. Cancer Res. 2020;80(18):3972–82. doi:10.1158/0008-5472.CAN-20-1072.
   PubMed Web of Science ®Google Scholar
• D’Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S. et al. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection. Sci Transl Med. 2022;14(657). doi:10.1126/scitranslmed.abo7604.
   PubMed Web of Science ®Google Scholar
• Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS. et al. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2020;130(12):6325–37. doi:10.1172/JCI140378.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ. et al. A phase IB trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347–62.e24. doi:10.1016/j.cell.2020.08.053.
   PubMed Web of Science ®Google Scholar
• Khattak A, Carlino M, Meniawy T, Ansstas G, Medina T, Taylor MH, Kim KB, McKean M, Long GV, Sullivan R. et al. A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201/Keynote-942 trial. AACR Annu Meet. 2023:CT001. doi:10.1158/1538-7445.AM2023-CT001
   Google Scholar
• Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–50. doi:10.1038/S41586-023-06063-Y.
   PubMed Web of Science ®Google Scholar
• Fritsch EF, Burkhardt UE, Hacohen N, Wu CJ. Personal neoantigen cancer vaccines: a road not fully paved. Cancer Immunol Res. 2020;8(12):1465–9. doi:10.1158/2326-6066.CIR-20-0526.
   PubMed Web of Science ®Google Scholar
• Wu J, Chen W, Zhou Y, Chi Y, Hua X, Wu J, Gu X, Chen S, Zhou Z. Tsnadb v2.0: the updated version of tumor-specific neoantigen database. Genomics, Proteomics Bioinform. 2022. doi:10.1016/J.GPB.2022.09.012.
   Web of Science ®Google Scholar
• Nagel R, Pataskar A, Champagne J, Agami R. Boosting antitumor immunity with an expanded neoepitope landscape. Cancer Res. 2022;82(20):3637–49. doi:10.1158/0008-5472.CAN-22-1525.
   PubMed Web of Science ®Google Scholar
• Shah NM, Jang HJ, Liang Y, Maeng JH, Tzeng SC, Wu A, Basri NL, Qu X, Fan C, Li A. et al. Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. Nat Genet. 2023;55(4):631–9. doi:10.1038/S41588-023-01349-3.
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Kataoka K, Chiba K, Okada A, Kogure Y, Tanaka H, Ogawa S, Miyano S. A comprehensive characterization of cis-acting splicing-associated variants in human cancer. Genome Res. 2018;28(8):1111–25. doi:10.1101/gr.231951.117.
   PubMed Web of Science ®Google Scholar
• Jung H, Lee D, Lee J, Park D, Kim YJ, Park WY, Hong D, Park PJ, Lee E. Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat Genet. 2015;47(11):1242–8. doi:10.1038/NG.3414.
   PubMed Web of Science ®Google Scholar
• Koh CM, Bezzi M, Low DHP, Ang WX, Teo SX, Gay FPH, Al-Haddawi M, Tan SY, Osato M, Sabò A. et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 2015;523(7558):96–100. doi:10.1038/NATURE14351.
   PubMed Web of Science ®Google Scholar
• Hoyos LE, Abdel-Wahab O. Cancer-specific splicing changes and the potential for splicing-derived neoantigens. Cancer Cell. 2018;34(2):181–3. doi:10.1016/J.CCELL.2018.07.008.
   PubMed Web of Science ®Google Scholar
• Ehx G, Larouche JD, Durette C, Laverdure JP, Hesnard L, Vincent K, Hardy MP, Thériault C, Rulleau C, Lanoix J. et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity. 2021;54(4):737–52.e10. doi:10.1016/j.immuni.2021.03.001.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399). doi:10.1126/SCITRANSLMED.AAA0984.
   PubMed Web of Science ®Google Scholar
• Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother (1991). 2019;42(4):126–35. doi:10.1097/CJI.0000000000000260.
   PubMed Web of Science ®Google Scholar
• Wang TY, Liu Q, Ren Y, Alam SK, Wang L, Zhu Z, Hoeppner LH, Dehm SM, Cao Q, Yang R. A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes. Mol Cell. 2021;81(10):2246–60.e12. doi:10.1016/J.MOLCEL.2021.03.028.
   PubMed Web of Science ®Google Scholar
• Kahles A, Van LK, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Caesar-Johnson SJ. et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34(2):211–24.e6. doi:10.1016/J.CCELL.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Bowling EA, Wang JH, Gong F, Wu W, Neill NJ, Kim IS, Tyagi S, Orellana M, Kurley SJ, Dominguez-Vidaña R. et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021;184(2):384–403.e21. doi:10.1016/J.CELL.2020.12.031.
   PubMed Web of Science ®Google Scholar
• Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, Knorr DA, Greenbaum B, Elhanati Y, Hogg SJ. et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184(15):4032–47.e31. doi:10.1016/J.CELL.2021.05.038.
   PubMed Web of Science ®Google Scholar
• Weinstein-Marom H, Hendel L, Laron EA, Sharabi-Nov A, Margalit A, Gross G. MHC-I presentation of peptides derived from intact protein products of the pioneer round of translation. FASEB J. 2019;33(10):11458–68. doi:10.1096/FJ.201802717RRR.
   PubMed Web of Science ®Google Scholar
• Becker JP, Helm D, Rettel M, Stein F, Hernandez-Sanchez A, Urban K, Gebert J, Kloor M, Neu-Yilik G, von Knebel Doeberitz M. et al. NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes. iScience. 2021;24(4):102389. doi:10.1016/J.ISCI.2021.102389.
   PubMed Web of Science ®Google Scholar
• Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, Munshi NC, Mayr C, Leslie CS. Widespread intronic polyadenylation diversifies immune cell transcriptomes. Nat Commun. 2018;9(1). doi: 10.1038/S41467-018-04112-Z.
   Google Scholar
• Avesson L, Barry G. The emerging role of RNA and DNA editing in cancer. Biochim Biophys Acta. 2014;1845(2):308–16. doi:10.1016/J.BBCAN.2014.03.001.
   PubMed Web of Science ®Google Scholar
• Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O. et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun. 2018;9(1). doi:10.1038/S41467-018-06405-9
   Google Scholar
• Garitano-Trojaola A, Agirre X, Prósper F, Fortes P. Long non-coding RNAs in haematological malignancies. Int J Mol Sci. 2013;14(8):15386–422. doi:10.3390/IJMS140815386.
   PubMed Web of Science ®Google Scholar
• Unfried JP, Sangro P, Prats-Mari L, Sangro B, Fortes P. The landscape of lncRNAs in hepatocellular carcinoma: a translational perspective. Cancers Basel. 2021;13(11):2651. doi:10.3390/CANCERS13112651.
   PubMed Web of Science ®Google Scholar
• Unfried JP, Fortes P. SMIM30, a tiny protein with a big role in liver cancer. J Hepatol. 2020;73(5):1010–12. doi:10.1016/J.JHEP.2020.07.015.
   PubMed Web of Science ®Google Scholar
• Mudge JM, Ruiz-Orera J, Prensner JR, Brunet MA, Calvet F, Jungreis I, Gonzalez JM, Magrane M, Martinez TF, Schulz JF. et al. Standardized annotation of translated open reading frames. Nat Biotechnol. 2022;40(7):994–9. doi:10.1038/S41587-022-01369-0.
   PubMed Web of Science ®Google Scholar
• Sandmann CL, Schulz JF, Ruiz-Orera J, Kirchner M, Ziehm M, Adami E, Marczenke M, Christ A, Liebe N, Greiner J. et al. Evolutionary origins and interactomes of human, young microproteins and small peptides translated from short open reading frames. Mol Cell. 2023;83(6):994–1011.e18. doi:10.1016/J.MOLCEL.2023.01.023.
   PubMed Web of Science ®Google Scholar
• Broeils LA, Ruiz-Orera J, Snel B, Hubner N, van Heesch S. Evolution and implications of de novo genes in humans. Nat Ecol Evol. 2023;7(6):804–15. doi:10.1038/S41559-023-02014-Y.
   PubMed Web of Science ®Google Scholar
• Ruiz Cuevas MV, Hardy MP, Hollý J, É B, Durette C, Courcelles M, Lanoix J, Côté C, Staudt LM, Lemieux S. et al. Most non-canonical proteins uniquely populate the proteome or immunopeptidome. Cell Rep. 2021;34(10):108815. doi:10.1016/J.CELREP.2021.108815.
   PubMed Web of Science ®Google Scholar
• Laumont CM, Vincent K, Hesnard L, Audemard É, Bonneil É, Laverdure JP, Gendron P, Courcelles M, Hardy MP, Côté C. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med. 2018;10(470). doi:10.1126/SCITRANSLMED.AAU5516.
   PubMed Web of Science ®Google Scholar
• Chothani SP, Adami E, Widjaja AA, Langley SR, Viswanathan S, Pua CJ, Zhihao NT, Harmston N, D’Agostino G, Whiffin N. et al. A high-resolution map of human RNA translation. Mol Cell. 2022;82(15):2885–99.e8. doi:10.1016/J.MOLCEL.2022.06.023.
   PubMed Web of Science ®Google Scholar
• Kesner JS, Chen Z, Shi P, Aparicio AO, Murphy MR, Guo Y, Trehan A, Lipponen JE, Recinos Y, Myeku N. et al. Noncoding translation mitigation. Nature. 2023;617(7960):395–402. doi:10.1038/S41586-023-05946-4.
   PubMedGoogle Scholar
• Laumont CM, Daouda T, Laverdure JP, É B, Caron-Lizotte O, Hardy MP, Granados DP, Durette C, Lemieux S, Thibault P. et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat Commun. 2016;7(1). doi:10.1038/NCOMMS10238.
   PubMedGoogle Scholar
• Chong C, Müller M, Pak HS, Harnett D, Huber F, Grun D, Leleu M, Auger A, Arnaud M, Stevenson BJ. et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat Commun. 2020;11(1). doi:10.1038/S41467-020-14968-9
   Web of Science ®Google Scholar
• Erhard F, Dölken L, Schilling B, Schlosser A. Identification of the cryptic HLA-I immunopeptidome. Cancer Immunol Res. 2020;8(8):1018–26. doi:10.1158/2326-6066.CIR-19-0886.
   PubMed Web of Science ®Google Scholar
• Guilloy N, Brunet MA, Leblanc S, Jacques JF, Hardy MP, Ehx G, Lanoix J, Thibault P, Perreault C, Roucou X. OpenCustomDB: integration of unannotated open reading frames and genetic variants to generate more comprehensive customized protein databases. J Proteome Res. 2023;22(5):1492–500. doi:10.1021/acs.jproteome.3c00054.
   PubMed Web of Science ®Google Scholar
• Prensner JR, Abelin JG, Kok LW, Clauser KR, Mudge JM, Ruiz-Orera J, Bassani-Sternberg M, Moritz RL, Deutsch EW, van Heesch S. What can ribo-seq, immunopeptidomics, and Proteomics tell us about the noncanonical proteome? Mol Cell Proteom: MCP. 2023;22(9):100631. doi:10.1016/J.MCPRO.2023.100631.
   PubMedGoogle Scholar
• Marlin E, Viu-Idocin C, Arrasate M, Aragón T. The role and therapeutic potential of the integrated stress response in amyotrophic lateral sclerosis. Int J Mol Sci. 2022;23(14):7823. doi:10.3390/IJMS23147823.
   PubMed Web of Science ®Google Scholar
• Bartok O, Pataskar A, Nagel R, Laos M, Goldfarb E, Hayoun D, Levy R, Körner PR, Kreuger IZM, Champagne J. et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. 2021;590(7845):332–7. doi:10.1038/S41586-020-03054-1.
   PubMedGoogle Scholar
• Champagne J, Pataskar A, Blommaert N, Nagel R, Wernaart D, Ramalho S, Kenski J, Bleijerveld OB, Zaal EA, Berkers CR. et al. Oncogene-dependent sloppiness in mRNA translation. Mol Cell. 2021;81(22):4709–21.e9. doi:10.1016/J.MOLCEL.2021.09.002.
   PubMed Web of Science ®Google Scholar
• Pataskar A, Champagne J, Nagel R, Kenski J, Laos M, Michaux J, Pak HS, Bleijerveld OB, Mordente K, Navarro JM. et al. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature. 2022;603(7902):721–7. doi:10.1038/S41586-022-04499-2.
   PubMed Web of Science ®Google Scholar
• Mohammed F, Cobbold M, Zarling AL, Salim M, Barrett-Wilt GA, Shabanowitz J, Hunt DF, Engelhard VH, Willcox BE. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol. 2008;9(11):1236–43. doi:10.1038/NI.1660.
   PubMed Web of Science ®Google Scholar
• Zarling AL, Polefrone JM, Evans AM, Mikesh LM, Shabanowitz J, Lewis ST, Engelhard VH, Hunt DF. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci U S A. 2006;103(40):14889–94. doi:10.1073/PNAS.0604045103.
   PubMed Web of Science ®Google Scholar
• Meyer VS, Drews O, Günder M, Hennenlotter J, Rammensee HG, Stevanovic S. Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J Proteome Res. 2009;8(7):3666–74. doi:10.1021/PR800937K.
   PubMed Web of Science ®Google Scholar
• Petersen J, Wurzbacher SJ, Williamson NA, Ramarathinam SH, Reid HH, Nair AKN, Zhao AY, Nastovska R, Rudge G, Rossjohn J. et al. Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc Natl Acad Sci U S A. 2009;106(8):2776–81. doi:10.1073/PNAS.0812901106.
   PubMed Web of Science ®Google Scholar
• Hanada KI, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature. 2004;427(6971):252–6. doi:10.1038/NATURE02240.
   PubMed Web of Science ®Google Scholar
• Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, Van Der Bruggen P, Boon T, Van Den Eynde BJ. An antigenic peptide produced by peptide splicing in the proteasome. Sci. 2004;304(5670):587–90. doi:10.1126/SCIENCE.1095522.
   PubMed Web of Science ®Google Scholar
• Groettrup M, Kirk CJ, Basler M. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol. 2010;10(1):73–8. doi:10.1038/NRI2687.
   PubMed Web of Science ®Google Scholar
• Michaux A, Larrieu P, Stroobant V, Fonteneau J-F, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J Immunol Res. 2014;192(4):1962–71. doi:10.4049/JIMMUNOL.1302032.
   Google Scholar
• Berkers CR, de Jong A, Schuurman KG, Linnemann C, Geenevasen JAJ, Schumacher TNM, Rodenko B, Ovaa H. Peptide splicing in the proteasome creates a novel type of antigen with an isopeptide linkage. J Immunol. 2015;195(9):4075–84. doi:10.4049/JIMMUNOL.1402454.
   PubMed Web of Science ®Google Scholar
• Mylonas R, Beer I, Iseli C, Chong C, Pak HS, Gfeller D, Coukos G, Xenarios I, Müller M, Bassani-Sternberg M. Estimating the contribution of proteasomal spliced peptides to the HLA-I ligandome. Molecular & Cellular Proteomics: MCP. 2018;17(12):2347–57. doi:10.1074/MCP.RA118.000877.
   PubMed Web of Science ®Google Scholar
• Kloetzel PM. Neo-splicetopes in tumor therapy: a lost case? Front Immunol. 2022;13. doi:10.3389/FIMMU.2022.849863.
   PubMedGoogle Scholar
• Lichti CF, Vigneron N, Clauser KR, Van den Eynde BJ, Bassani-Sternberg M. Navigating critical challenges associated with immunopeptidomics-based detection of proteasomal spliced peptide candidates. Cancer Immunol Res. 2022;10(3):275–84. doi:10.1158/2326-6066.CIR-21-0727.
   PubMed Web of Science ®Google Scholar
• Chong C, Coukos G, Bassani-Sternberg M. Identification of tumor antigens with immunopeptidomics. Nat Biotechnol. 2022;40(2):175–88. doi:10.1038/S41587-021-01038-8.
   PubMed Web of Science ®Google Scholar
• Ingolia NT, Hussmann JA, Weissman JS. Ribosome profiling: global views of translation. Cold Spring Harb Perspect Biol. 2019;11(5):a032698. doi:10.1101/CSHPERSPECT.A032698.
   PubMed Web of Science ®Google Scholar
• Menschaert G, Van Criekinge W, Notelaers T, Koch A, Crappé J, Gevaert K, Van Damme P. Deep proteome coverage based on ribosome profiling aids mass spectrometry-based protein and peptide discovery and provides evidence of alternative translation products and near-cognate translation initiation events. Mol Cell Proteom: MCP. 2013;12(7):1780–90. doi:10.1074/MCP.M113.027540.
   PubMed Web of Science ®Google Scholar
• Ingolia NT, Ghaemmaghami S, Newman JRS, Weissman JS. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Sci. 2009;324(5924):218–23. doi:10.1126/SCIENCE.1168978.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sotta N, Yamazumi Y, Yamashita Y, Miwa K, Murota K, Chiba Y, Hirai MY, Akiyama T, Onouchi H. et al. The minimum open reading frame, AUG-stop, induces boron-dependent ribosome stalling and mRNA degradation. Plant Cell. 2016;28(11):2830–49. doi:10.1105/TPC.16.00481.
   PubMed Web of Science ®Google Scholar
• Al-Turki TM, Griffith JD. Mammalian telomeric RNA (TERRA) can be translated to produce valine-arginine and glycine-leucine dipeptide repeat proteins. Proc Natl Acad Sci U S A. 2023;120(9). doi:10.1073/PNAS.2221529120.
   PubMedGoogle Scholar
• Calviello L, Ohler U. Beyond read-counts: ribo-seq data analysis to understand the functions of the transcriptome. Trends Genet. 2017;33(10):728–44. doi:10.1016/J.TIG.2017.08.003.
   PubMed Web of Science ®Google Scholar
• Cao X, Khitun A, Na Z, Dumitrescu DG, Kubica M, Olatunji E, Slavoff SA. Comparative proteomic profiling of unannotated microproteins and alternative proteins in human cell lines. J Proteome Res. 2020;19(8):3418–26. doi:10.1021/ACS.JPROTEOME.0C00254.
   PubMed Web of Science ®Google Scholar
• Ma J, Diedrich JK, Jungreis I, Donaldson C, Vaughan J, Kellis M, Yates JR, Saghatelian A. Improved identification and analysis of small open reading frame encoded polypeptides. Anal Chem. 2016;88(7):3967–75. doi:10.1021/ACS.ANALCHEM.6B00191.
   PubMed Web of Science ®Google Scholar
• Ouspenskaia T, Law T, Clauser KR, Klaeger S, Sarkizova S, Aguet F, Li B, Christian E, Knisbacher BA, Le PM. et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022;40(2):209–17. doi:10.1038/S41587-021-01021-3.
   PubMed Web of Science ®Google Scholar
• Creech AL, Ting YS, Goulding SP, Sauld JFK, Barthelme D, Rooney MS, Addona TA, Abelin JG. The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction. Proteomics. 2018;18(12). doi: 10.1002/PMIC.201700259.
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteom: MCP. 2015;14(3):658–73. doi:10.1074/MCP.M114.042812.
   PubMed Web of Science ®Google Scholar
• Illing PT, Ramarathinam SH, Purcell AW. New insights and approaches for analyses of immunopeptidomes. Curr Opin Immunol. 2022;77:102216. doi:10.1016/J.COI.2022.102216.
   PubMed Web of Science ®Google Scholar
• MacLachlan BJ, Dolton G, Papakyriakou A, Greenshields-Watson A, Mason GH, Schauenburg A, Besneux M, Szomolay B, Elliott T, Sewell AK. et al. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. J Biol Chem. 2019;294(52):20246–58. doi:10.1074/JBC.RA119.009437.
   PubMed Web of Science ®Google Scholar
• van Hateren A, Elliott T. Visualising tapasin- and TAPBPR-assisted editing of major histocompatibility complex class-I immunopeptidomes. Curr Opin Immunol. 2023;83:102340. doi:10.1016/J.COI.2023.102340.
   PubMed Web of Science ®Google Scholar
• O’Donnell TJ, Rubinsteyn A, Laserson U. Mhcflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 2020;11(1):42–8.e7. doi:10.1016/J.CELS.2020.06.010.
   PubMed Web of Science ®Google Scholar
• Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449–W54. doi:10.1093/NAR/GKAA379.
   PubMed Web of Science ®Google Scholar
• Rock KL, Reits E, Neefjes J. Present yourself! By MHC class I and MHC class II molecules. Trends Immunol. 2016;37(11):724–37. doi:10.1016/J.IT.2016.08.010.
   PubMed Web of Science ®Google Scholar
• Gessulat S, Schmidt T, Zolg DP, Samaras P, Schnatbaum K, Zerweck J, Knaute T, Rechenberger J, Delanghe B, Huhmer A. et al. Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning. Nat Methods. 2019;16(6):509–18. doi:10.1038/S41592-019-0426-7.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Zolg DP, Graber M, Gessulat S, Schmidt T, Schnatbaum K, Schwencke-Westphal C, Seifert P, de Andrade Krätzig N, Zerweck J. et al. Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics. Nat Commun. 2021;12(1). doi:10.1038/s41467-021-24263-w.
   Web of Science ®Google Scholar
• Bouwmeester R, Gabriels R, Hulstaert N, Martens L, Degroeve S. DeepLC can predict retention times for peptides that carry as-yet unseen modifications. Nat Methods. 2021;18(11):1363–9. doi:10.1038/S41592-021-01301-5.
   PubMed Web of Science ®Google Scholar
• Omenn GS. Reflections on the HUPO human proteome project, the flagship project of the human proteome organization, at 10 years. Mol Cell Proteom: MCP. 2021;20:100062. doi:10.1016/J.MCPRO.2021.100062.
   PubMed Web of Science ®Google Scholar